• 1. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 2. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 5. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Thiophenes Thiophene carboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Thiophenes Thiophene carboxylic acids and derivatives Thiophene carboxylic acids

Recent Advances in Dibromothiophene-3,4-dicarboxylic Acid (CAS: 190723-12-7) Research: A Comprehensive Review

Dibromothiophene-3,4-dicarboxylic acid (CAS: 190723-12-7) has emerged as a compound of significant interest in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. Recent studies have highlighted its role as a versatile building block in the synthesis of novel bioactive molecules, particularly in the development of enzyme inhibitors and small-molecule modulators of protein-protein interactions. This research briefing aims to provide a comprehensive overview of the latest advancements in the understanding and application of this compound, focusing on its chemical properties, synthetic methodologies, and biological activities.

One of the most notable developments in the study of dibromothiophene-3,4-dicarboxylic acid is its application in the design of covalent inhibitors targeting cysteine proteases. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit potent inhibitory activity against cathepsin B, a protease implicated in various pathological conditions, including cancer and inflammatory diseases. The researchers utilized a structure-based drug design approach, leveraging the compound's bromine substituents for selective covalent modification of the enzyme's active site cysteine residue. This finding opens new avenues for the development of targeted therapies for protease-dependent diseases.

In the realm of materials science, dibromothiophene-3,4-dicarboxylic acid has shown promise as a precursor for the synthesis of conjugated polymers with unique electronic properties. A recent publication in Advanced Materials reported the successful incorporation of this compound into donor-acceptor copolymers, resulting in materials with enhanced charge transport characteristics suitable for organic electronic applications. The presence of both electron-withdrawing carboxylic acid groups and electron-donating thiophene moieties in the molecular structure contributes to the tunable electronic properties of the resulting polymers, making them particularly valuable for optoelectronic device applications.

From a synthetic chemistry perspective, several innovative methodologies have been developed for the modification and functionalization of dibromothiophene-3,4-dicarboxylic acid. A 2022 study in Organic Letters described a palladium-catalyzed cross-coupling strategy that enables selective modification of the bromine positions while preserving the carboxylic acid functionalities. This approach has significantly expanded the structural diversity accessible from this scaffold, facilitating the rapid generation of compound libraries for biological screening. The study also reported improved synthetic yields through optimized reaction conditions, addressing previous challenges in the large-scale production of this compound.

The biological evaluation of dibromothiophene-3,4-dicarboxylic acid derivatives has revealed several interesting pharmacological properties. Recent in vitro studies have demonstrated that certain derivatives exhibit potent anti-inflammatory activity by inhibiting the NF-κB signaling pathway. Additionally, preliminary investigations into the compound's metal-chelating properties suggest potential applications in the development of novel radiopharmaceuticals and diagnostic agents. These findings underscore the compound's versatility and highlight its potential as a valuable scaffold in medicinal chemistry.

Looking forward, the research community anticipates several promising directions for further investigation of dibromothiophene-3,4-dicarboxylic acid. These include the exploration of its potential in targeted drug delivery systems, the development of novel antimicrobial agents based on its structural framework, and the investigation of its applications in supramolecular chemistry. As synthetic methodologies continue to advance and our understanding of its biological activities deepens, this compound is poised to play an increasingly important role in both basic research and applied pharmaceutical development.

• 937640-21-6(dimethyl 2,5-dibromothiophene-3,4-dicarboxylate)
• 289470-44-6(Ethyl 2,5-dibromothiophene-3-carboxylate)
• 100523-84-0(5-Bromothiophene-3-carboxylic acid)
• 7311-70-8(2,5-Dibromothiophene-3-carboxylic acid)
• 221061-14-9(2-Bromo-5-methylthiophene-3-carboxylic acid)
• 76360-43-5(Methyl 2-bromothiophene-3-carboxylate)
• 24287-95-4(2-Bromothiophene-3-carboxylic acid)
• 89280-91-1(Methyl 2,5-dibromothiophene-3-carboxylate)
• 1015423-45-6(4,6-Dibromothieno3,4-cfuran-1,3-dione)
• 632325-50-9(Ethyl 2-bromothiophene-3-carboxylate)